In animal models, sclerostin antibody treatment reverses the adverse effects of T2D on bone mass and strength and improves bone defect regeneration.[48, 57] Previous meta‐analysis reported increased sclerostin in both T1D and T2D.[22] In addition, sclerostin gene expression was reported to be higher in bone samples of people with T2D than those without the disease.[26] These data suggest that sclerostin might be involved in bone fragility in T1D and T2D, making antisclerostin antibodies a candidate to treat bone fragility in the disease. This evidence concerns the gene SOST and type 1 diabetes mellitus.